AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.

7,2',4'-Trihydroxy-5-methoxy-3-arylcoumarin shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells.

Thioguanine is an antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.